抗性激素依赖性肿瘤药物引起的骨丢失

Anti-sex hormone-dependent neoplasm agents-induced bone loss

一般的抗肿瘤化疗药物可引起骨丢失，而抗性激素依赖性肿瘤药物因其抑制雌激素／孕激素或雄激素的合成与分泌，导致雌激素和（或）雄激素缺乏和两者比例失调，骨丢失的发生率几乎为100％。以骨转换升高为特征的抗性激素依赖性肿瘤药物治疗往往导致多发性脆性骨折，故必须注重其预防和治疗。本文重点评论该类药物所致骨丢失的病因、发生机制和防治。

Chemotherapy can induce bone loss. It is especially severe and the incidence of estimated bone loss may be as high as almost 100% for cancer patients treated with anti-sex hormone agents because of inhibition and deficiency of estrogens and/or androgens with the inappropriate ratio of two hormones during and after therapy. Anti-sex hormone-dependent neoplasm agents-induced bone loss, characterized by an increase of bone turnover rate, should be treated in the early stage in order to prevent it from deterioration and bone fractures. The etiology, mechanism and clinical management of anti-sex hormone-dependent neoplasm agents-induced bone loss are briefly discussed in this review.